These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Antiretroviral chemotherapy against human immunodeficiency virus (hiv) infection: perspective for therapy of hepatitis B virus infection. Mitsuya H; Broder S Cancer Detect Prev; 1989; 14(2):299-308. PubMed ID: 2695248 [TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy for human immunodeficiency virus infection in 1997. Katzenstein DA West J Med; 1997 May; 166(5):319-25. PubMed ID: 9217434 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic approaches to human immunodeficiency virus infections. Baba M Fukushima J Med Sci; 1992 Jun; 38(1):1-18. PubMed ID: 1284048 [TBL] [Abstract][Full Text] [Related]
7. Protease inhibitor trials moving to next phase. AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral drug treatment for HIV/AIDS. Goldschmidt RH; Moy A Am Fam Physician; 1996 Aug; 54(2):574-80, 587-8. PubMed ID: 8701838 [TBL] [Abstract][Full Text] [Related]
9. [Drugs active against retroviruses]. Brun-Vézinet F; Descamps D Rev Prat; 1997 Mar; 47(6):631-8. PubMed ID: 9183937 [TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. Fischl MA AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785 [TBL] [Abstract][Full Text] [Related]
14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy. Justesen US Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):20-31. PubMed ID: 16433887 [TBL] [Abstract][Full Text] [Related]
16. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Gerber JG Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896 [TBL] [Abstract][Full Text] [Related]
17. Abacavir: new preparation. Risks limit the value. Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740 [TBL] [Abstract][Full Text] [Related]
18. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Vella S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511 [TBL] [Abstract][Full Text] [Related]
19. Current approaches to treatment for HIV-1 infection. Powderly WG J Neurovirol; 2000 May; 6 Suppl 1():S8-S13. PubMed ID: 10871760 [TBL] [Abstract][Full Text] [Related]
20. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F; Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]